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ABSTRACT
Aim The aim of this official guideline published by the Ger-
man Society of Gynecology and Obstetrics (DGGG) and coor-
dinated with the German Society of Urology (DGU) and the
German Society of Reproductive Medicine (DGRM) is to pro-
vide consensus-based recommendations, obtained by evalu-
ating the relevant literature, on counseling and fertility pres-
ervation for prepubertal girls and boys as well as patients of
reproductive age. Statements and recommendations for girls
and women are presented below. Statements or recommen-
dations for boys and men are not the focus of this guideline.
Methods This S2k guideline was developed at the suggestion
of the guideline commission of the DGGG, DGU and DGRM
and represents the structured consensus of representative
members from various professional associations (n = 40).
Recommendations The guideline provides recommenda-
tions on counseling and fertility preservation for women and
girls which take account of the patientʼs personal circum-
stances, the planned oncologic therapy and the individual risk
profile as well as the preferred approach for selected tumor
entities.
ZUSAMMENFASSUNG
Ziel Das Ziel dieser offiziellen Leitlinie, die von der Deutschen
Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) publi-
ziert und zusammen mit der Deutschen Gesellschaft für Uro-
logie (DGU) sowie Deutschen Gesellschaft für Reproduktions-
medizin (DGRM) koordiniert wurde, ist es, durch die Evaluation
der relevanten Literatur konsensbasierte Handlungsempfehlun-
gen für die Beratung und den Einsatz von fertilitätserhaltenden
Maßnahmen bei präpubertären Mädchen und Jungen sowie für
Patienten/-innen im reproduktiven Alter zu geben. Im Folgen-
dem werden die Statements und Empfehlungen für Mädchen
und Frauen dargestellt. Die Statements und Empfehlungen für
Jungen und Männer sind nicht Inhalt dieser Publikation.
Methoden Diese S2k-Leitlinie wurde durch einen strukturier-
ten Konsens von repräsentativen Mitgliedern verschiedener
Fachgesellschaften (n = 40) im Auftrag der Leitlinienkommis-
sion der DGGG, DGU und DGRM entwickelt.
Empfehlungen Es werden Empfehlungen zur Beratung und
dem Einsatz von fertilitätserhaltenden Maßnahmen bei Pa-
tientinnen unter Berücksichtigung der Lebensumstände, der
geplanten onkologischen Therapie und des individuellen Risi-
koprofils dargestellt sowie über das Vorgehen bei ausgewähl-
ten Tumorentitäten.
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Abbreviations
ABVD doxorubicin, bleomycin, vinblastine, dacarbazine
AC doxorubicin, cyclophosphamide
ALL acute lymphoblastic leukemia
AMH anti-Müllerian hormone
AML acute myeloid leukemia
ART assisted reproductive technologies
BEACOPP bleomycin, etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine,
prednisone
BOT borderline tumor
CAF cyclophosphamide, adriamycin, fluorouracil
CEF cyclophosphamide, epirubicin, 5-flourouracil
ChlVPP/EVA hybrid COPP
chlorambucil, vinblastine, procarbazine, prednisone/
etoposide, vincristine, doxorubicin
CHOP cyclophosphamide, doxorubicin, vincristine,
prednisolone
CI confidence interval
CMF cyclophosphamide, methotrexate, 5-fluorouracil
CML chronic myelogenous leukemia
CVP cyclophosphamide, vincristine, prednisone
DMSO dimethyl sulfoxide
EC epirubicin, cyclophosphamide
ESD effective sterilizing dose
FOLFOX folinic acid (leucovorin), 5-fluorouracil, oxaliplatin
GnRH gonadotropin-releasing hormone
GnRHa gonadotropin-releasing hormone agonist
Gy Gray
HL Hodgkinʼs lymphoma
MVPP mustine, vinblastine, procarbazine, prednisolone
NHL non-Hodgkinʼs lymphoma
OR odds ratio
POI premature ovarian insufficiency
RR relative risk
SCT stem cell transplantation
TAC paclitaxel (taxol), doxorubicin (adriamycin),
cyclophosphamide
TKI tyrosine kinase inhibitorsII Guideline Application
Purpose and Objectives
The purpose of this guideline is to provide recommendations for
action with regard to counseling and fertility preservation for pre-
pubertal girls and women of reproductive age with oncologic dis-
ease which take account of the patientsʼ personal circumstances
and risk profile. The aim is to increase the rate of successful preg-
nancies after completing oncologic therapy and to improve the
patientsʼ quality of life.Dittrich R et al. Fertility Preservation for… Geburtsh Frauenheilk 2018; 78: 567–584Targeted areas of patient care
▪ Outpatient care
▪ Inpatient care
▪ Semi-residential care
Target patient groups
The guideline is aimed at all prepubertal girls and patients of re-
productive age who require gonadotoxic treatment for malignant
disease.
Target user group/target audience
This guideline is aimed at all physicians and medical professionals
involved in the care of patients who require gonadotoxic therapy.
The principal among these are: gynecologists, reproductive
medicine physicians, andrologists, urologists, oncologists, radio-
oncologists, general practitioners, pediatricians, pathologists,
psycho-oncologists.
Adoption of the guideline and period of validity
This guideline is valid from November 1, 2017 to October 31,
2020. Because of the contents of the guideline, this period of va-
lidity is only an estimate. If there are important changes to the
evidence, then amendments to the guideline will be published be-
fore the period of validity has expired, once the new evidence has
been carefully reviewed in accordance with the methodology of
the AWMF.III Methodology
Basic principles
The methodology used to prepare this guideline is determined by
the class to which the guideline is assigned. The AWMF Guidance
Manual (version 1.0) has set out the respective rules and regula-
tions for the classification of guidelines. Guidelines are differenti-
ated into lowest (S1), intermediate (S2) and highest (S3) class.
The lowest class is defined as a summary of recommendations
for action compiled by a non-representative group of experts. In
2004 the S2 class was divided into two subclasses: a systematic
evidence-based subclass (S2e) and a structural consensus-based
subclass (S2k). The highest S3 class combines both approaches.
This guideline is classified as: S2k
Grading of recommendations
While the description of the quality of the evidence (strength of
evidence) serves as an indication for the robustness of the publi-
cized data and therefore expresses the extent of certainty/uncer-
tainty about the data, the classification of the level of recommen-
dation reflects the result of weighing up the desirable and adverse
consequences of alternative approaches.571
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envisaged for S2k-level guidelines. The level of recommendation
is differentiated by syntax, not by symbols. The syntax used to
grade the level of recommendation is described in the back-
ground text (▶ Table 2).▶ Table 2 Grading of recommendations.
Description of level of recommendation Syntax
Strong recommendation, highly binding must/must not
Recommendation, moderately binding should/should not
Open recommendation, not binding may/may not
Consensus-based Recommendation 1.R1
Expert consensus Strength of consensus ++
Assessing the risk of possible infertility and the choice of method(s) for fer-
tility preservationmust be done by an interdisciplinary panel and discussed
with the patient in good time before the start of oncologic therapy.
Consensus-based Statement 1.S1
Expert consensus Strength of consensus +++
Counseling about concepts to preserve fertility must be an integral part of
every patientʼs oncologic treatment andmust take account of the patientʼs
personal circumstances, recommended oncologic therapy and individual
risk profile.Statements
Expert statements included in this guideline which are not recom-
mendations for action but simple statements of fact are referred
to as Statements. It is not possible to provide a level of evidence
for these statements.
Achieving consensus and strength of consensus
As part of structured consensus-based decision-making (S2k/S3
level), authorized participants present at consensus sessions vote
on draft Statements and Recommendations. Discussions at the
sessions can lead to significant changes in the wording of State-
ments and Recommendations. The extent of agreement, which
depends on the number of participants, is then determined at
the end of the session (▶ Table 3).▶ Table 3 Classification on extent of agreement following consensus-
based decision-making.
Symbol Strength of consensus Extent of agreement in percent
+++ Strong consensus > 95% of participants agree
++ Consensus > 75–95% of participants agree
+ Majority agreement > 50–75% of participants agree
– No consensus < 50% of participants agreeExpert consensus
As the name implies, this term refers to consensus decisions taken
with regard to specific Recommendations/Statements without a
previous systematic search of the literature (S2k) or when evi-
dence is lacking (S2e/S3). The term “expert consensus” (EC) used
here is synonymous with terms used in other guidelines such as
“good clinical practice” (GCP) or “clinical consensus point” (CCP).
The strength of the recommendation is graded as previously de-
scribed in the chapter “Grading of recommendations”; the
strength of consensus is only indicated semantically (“must”/
“must not” or “should”/“should not” or “may”/“may not”) with
no use of symbols.572IV Guideline
Statements and Recommendations on fertility preservation for
girls and women with oncologic disease are presented below.
1 Introduction to Fertility Protection for Persons
Diagnosed with Oncologic Disease
1.2 Importance and problems of fertility protection
for persons diagnosed with cancer
Oncologic therapies often lead to partial or complete impairment
of gonadal function in both men and women along with the po-
tential loss of germ cells. Faced by the impact of a life-threatening
disease, subsequent infertility may appear to be a minor issue for
non-affected persons. For many of the patients themselves, how-
ever, premature ovarian insufficiency or sterility is a very stressful
situation for both the affected patient and their partner [2,3].2 Causes of Gonadal Toxicity in Women
2.1 Gonadal damage from surgery
Depending on the extent of radical surgery, gynecologic onco-
logic disease can result in sterility following complete or partial re-
moval of the uterus and/or ovaries. Fertility-preserving surgery for
various tumor entities is discussed in Chapter 4.1 of the long ver-
sion of the guideline.
2.2 Gonadal toxicity from chemotherapy
The gonadal toxicity of individual chemotherapeutic drugs de-
pends on their mechanism of action, the administered dose, the
duration of therapy, the way in which therapy is administered,
concomitant therapeutic treatments such as simultaneous radio-
therapy or ovary-removal surgery, the patientʼs age, and the pa-
tientʼs individual disposition (▶ Table 4).Dittrich R et al. Fertility Preservation for… Geburtsh Frauenheilk 2018; 78: 567–584
▶ Table 4 Ovarian toxicity of different chemotherapeutic drugs
(modified from [4,5]).
Risk Regimen/Substance
High risk
(> 80% risk of perma-
nent amenorrhea)
▪ CMF, CEF, CAF, TAC × 6 for women aged
≥ 40 years
▪ Conditioning for stem cell transplantation
(particularly alkylating agent-based myelo-
ablative conditioning with busulfan, cyclo-
phosphamide, melphalan)
▪ BEACOPP × 6–8 for women aged > 35 years
Intermediate risk
(40–60% risk of per-
manent amenorrhea)
▪ CMF, CEF, CAF, TAC × 6 for women aged
30–39 years
▪ AC × 4 for women aged ≥ 40 years
▪ AC or EC × 4→ taxane
▪ BEACOPP × 6–8 for women aged 25–35 years
▪ CHOP × 6 for women aged ≥ 35 years
▪ Standard therapies for bone and soft tissue
sarcomas
Low risk
(< 20% risk of perma-
nent amenorrhea)
▪ CMF, CEF, CAF, TAC × 6 for women aged
≤ 30 years
▪ AC × 4 for women aged ≤ 40 years
▪ BEACOPP × 6–8 for women aged < 25 years
▪ ABVD × 2–4
▪ CHOP × 6 for women aged < 35 years
▪ CVP
▪ AML-type therapy (anthracyclines/
cytarabine)
▪ ALL-type therapy (multi-agent)
▪ FOLFOX for women aged ≤ 40 years
Very low or no
risk of permanent
amenorrhea
▪ Methotrexate
▪ Fluorouracil
▪ Vincristine
Consensus-based Statement 2.R2
Expert consensus Strength of consensus +++
Women scheduled to receive a potentially gonadotoxic dose of chemo-
therapeutic drugs must be informed about the risk of ovarian insufficiency
and about methods to preserve fertility.
Consensus-based Statement 2.S3
Expert consensus Strength of consensus +++
The negative impact of the gonadal toxicity of chemotherapies increases
with patient age.Not all patients in a specific age groupwho receive therapy
according to a defined regimen will develop the same fertility disorder.
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2.3.1 Ovarian radiation damage
(▶ Table 5)▶ Table 5 Radiotoxicity and ovarian insufficiency (modified from [6]).
Effective sterilizing dose (ESD) Ovarian radiation dose (Gy)
No relevant effect 0.6
No relevant effect at < 40 years 1.5
0 years 20.3
10 years 18.4
20 years 16.5
30 years 14.3
40 years 6
Consensus-based Statement 2.S4
Expert consensus Strength of consensus +++
Whether women develop ovarian insufficiency depends on the radiation
dose, the age when the patient was exposed to radiation and the volume
of irradiated ovarian tissue.
Consensus-based Recommendation 2.R3
Expert consensus Strength of consensus +++
Patients who are scheduled to receive radiotherapy which will also irradiate
the anatomical area of the ovaries must be informed about the risk of
ovarian damage andmust bemade aware ofmethodswhich could preserve
their fertility.2.3.2 Tubal radiation damage
Radiogenic tubal changes can lead to a loss of function, resulting
in limited fertility. Extrauterine pregnancies and their associated
subsequent complications can occur, even if ovarian and uterine
function have been preserved. Nothing is known about tubal tol-
erance doses.
2.3.3 Uterine radiation damage
In contrast to chemotherapy, radiotherapy can affect uterine
function in addition to affecting the ovaries. Here again, the effect
depends on the dose; the dose-response relationship has not yet
been clearly defined [7].Consensus-based Statement 2.S5
Expert consensus Strength of consensus +++
Irradiation of the uterus can lead to uterine and tubal sterility and to in-
creased pregnancy risks such as preterm birth, miscarriage and lower birth
weight of the infant.
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hypophyseal axisConsensus-based Recommendation 2.R4
Expert consensus Strength of consensus +++
Before undergoing radiotherapy of the head region, patients must be in-
formed about the risk of damaging the hypothalamic/hypophyseal axis and
the consequences of this damage.
Consensus-based Statement 2.S6
Expert consensus Strength of consensus +++
Data on gonadal toxicity of tamoxifen are limited and inconsistent; there
are no data on the possible effects of aromatase inhibitors combined with
GnRH agonists. A gonadotoxic effect is unlikely.
Consensus-based Statement 2.S7
Expert consensus Strength of consensus +++
Themost important fertility-reducing effect of endocrine therapy used to
treat breast cancer is the length of the treatment, as it postpones the time2.4 Gonadal toxicity through immunotherapy
or targeted therapiesConsensus-based Recommendation 2.R5
Expert consensus Strength of consensus +++
Women receiving therapy with bevacizumab should be informed about the
risk of ovarian insufficiency and about methods to preserve fertility.
Consensus-based Recommendation 2.R2
Expert consensus Strength of consensus +++
Patients who receive immunotherapy or targeted therapy should be in-
formed about the unclear risk of ovarian insufficiency and about methods
to preserve fertility.
Risk assessment of impac
Discussion of issues with
If the patient is interested
referral to a specialist with expertise
Tried and tested treatment method
Cryopreservation of fertilized
and unfertilized oocytes
Cryopreservation of ovarian tissue
Fertility-preserving surgery
Ovariopexy
GnRH agonists
▶ Fig. 1 Flow diagram of potential approaches to protect the fertility of girl
therapy.
5742.5 Gonadal toxicity from endocrine therapieswhen the patient can have children to a stage in life when patient has
reduced ovarian reserve.
Consensus-based Recommendation 2.R7
Expert consensus Strength of consensus ++
Ways of protecting fertility such as cryopreservation of fertilized and/or
unfertilized oocytes or ovarian tissue should be discussed with women
receiving endocrine therapy alone (5–10 years) to treat breast cancer.
Consensus-based Recommendation 2.R8
Expert consensus Strength of consensus ++
The possibility of postponing or interrupting endocrine therapy may be
discussed with the patient if this would allow her to have children early.4 Methods of Fertility Protection for Girls
and Women
(▶ Figs. 1 and 2)t of therapy on fertility
the affected patient
in fertility preservation:
in the field of gonadal protection
s: Experimental
treatment methods:
In vitro maturation
s and women after the onset of menarche before they start gonadotoxic
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Consensus-based Statement 4.S47
Expert consensus Strength of consensus ++
The data is still contradictory, so administering GnRH agonists as the only
method for fertility protection is not sufficient.
Consensus-based Statement 4.S58
Expert consensus Strength of consensus +++
Because of the contradictory study results, it is currently not possible
to evaluate the benefit of administering a GnRH agonist.
Gynecologic
tumors
Fertility-preserving
surgery
Radiation
of the pelvis
Ovariopexy
and/or
and/or
Cryopreservation
of ovarian tissue
Cryopreservation
of fertilized and
unfertilized oocytes
Time to the start of chemotherapy
2 weeks≥
Non-estrogen-
dependent tumor
Cryopreservation
of ovarian tissue
and/or
and/or
Cryopreservation
of fertilized and
unfertilized oocytes
GnRH agonists
Estrogen-
dependent tumor
Cryopreservation
of ovarian tissue
After weighing up
the benefits and risks
for the individual:
Cryopreservation
of fertilized and
unfertilized oocytes
and/or
GnRH agonists
Time to the start
of chemotherapy
< 2 weeks
Cryopreservation
of ovarian tissue
GnRH agonists
In vitro maturation
of oocytes
and/or
and/or
▶ Fig. 2 Fertility protection for women based on oncologic therapy and the available timeframe (modified from [1]).4.1 Organ-preserving surgery
There are a number of S3 guidelines on the treatment of patients
with malignant ovarian tumors, cervical cancer und endometrial
cancer. To prevent discrepancies between guidelines, the guide-
line coordinators of the S3 guidelines and the coordinators of the
S2k guideline on fertility preservation unanimously agreed to in-
corporate the relevant Statements, Recommendations and back-
ground texts from the S3 guidelines into the S2k guideline. The
relevant Recommendations and Statements are available in the
long version of the guideline.
4.2 Ovariopexy and gonadal protection for radiotherapyConsensus-based Statement 4.S25
Expert consensus Strength of consensus +++
Transposition of the ovaries out of the area which will be irradiatedmay
reduce the risk of radiogenic ovarian insufficiency.
Consensus-based Recommendation 4.R33
Expert consensus Strength of consensus +++
The possibility of an ovariopexy to preserve ovarian function must be dis-
cussed before commencing radiotherapy/radiochemotherapy of the lesser
pelvis.
Consensus-based Statement 4.S36
Expert consensus Strength of consensus +++
If ovariopexy is performed, ovarian tissue may be harvested at the same
time for cryopreservation.
Dittrich R et al. Fertility Preservation for… Geburtsh Frauenheilk 2018; 78: 567–5844.3 GnRH agonistsConsensus-based Recommendation 4.R34
Expert consensus Strength of consensus +++
Depending on the underlying tumor entity, GnRH agonists may be offered
as a fertility protection measure if the patient has been informed in detail.4.4 Cryopreservation of fertilized or unfertilized
oocytesConsensus-based Statement 4.S19
Expert consensus Strength of consensus +++
Cryopreservation of fertilized and unfertilized oocytes is an established
technique in reproductive medicine which can be used before starting
gonadotoxic therapy.
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▶ Table 8 Pregnancy outcomes for blastocysts after slow freezing or
GebFra Science | Guideline4.4.1 Controlled ovarian stimulation to harvest oocytes
in cancer patientsvitrification (modified from [11] and [8]).
Slow freezing Vitrification
Rate of transferred blastocysts
per cryopreservation/thawing
71.4% 84.5%*
Rate of clinical pregnancies per
transferred blastocyst
23.8% 32.7%**
Rate of live births per transferred
blastocyst
17.7% 24.8%***
* p = significant, ** ARR: 1.38, 95% CI: 1.32–1.45, *** ARR: 1.41, 95% CI:
1.34–1.49
Consensus-based Statement 4.S20
Expert consensus Strength of consensus +++
A protocol with the lowest possible risk of ovarian hyperstimulation syn-
drome should be used for ovarian stimulation treatment to protect fertility.4.4.2 Cryopreservation of unfertilized oocytes
(▶ Table 6)▶ Table 6 Outcomes for unfertilized oocytes after slow freezing or
vitrification (modified from [8] and [9]).
Slow freezing Vitrification
Survival rate per unfertilized oocyte
after cryopreservation/thawing
45–67% 80–90%
Fertilization rate per unfertilized
oocyte after cryopreservation/thawing
54–68% 76–83%
Clinical pregnancy rate/transfers 11.6% 44.9%
(p = 0.002)
Congenital malformation rate 0.5% 1.3%
Consensus-based Statement 4.S21
Expert consensus Strength of consensus ++
In contrast to the cryopreservation of fertilized oocytes, the cryopreserva-
tion of unfertilized oocytes is not associated with a significantly increased
rate of malformations or developmental deficits in children.
Consensus-based Recommendation 4.R35
Expert consensus Strength of consensus +++
The cryopreservation of unfertilized oocytes must be additionally offered,
even if the patient has a partner.
Consensus-based Statement 4.S22
Expert consensus Strength of consensus ++
Cryopreservation of ovarian tissue is an establishedmethod to restore
fertility after receiving treatment for cancer.
Consensus-based Statement 4.S23
Expert consensus Strength of consensus ++
Cryopreservation of ovarian tissue may be carried out at any time of
the menstrual cycle and does not lead to any relevant delay in oncologic
therapy.4.4.3 Cryopreservation of fertilized oocytes
(▶ Tables 7 and 8)▶ Table 7 Survival rate and development of embryos after slow freez-
ing or vitrification (open/closed) (modified from [10]).
Slow freezing Vitrification
(open/closed)
Survival rate per embryo after
cryopreservation/thawing
63.8% 89.4%*/87.6%*
Rate of intact morphology of all
blastomeres per embryo after
cryopreservation/thawing
44.3% 80.1%*/76.1%*
* p < 0,001
5764.5 Cryopreservation of ovarian tissue4.5.1 Harvesting and transport of ovarian tissueConsensus-based Recommendation 4.R36
Expert consensus Strength of consensus +++
The harvested tissue must be cooled (4–8°C) during its transportation to
a center which specializes in cryopreservation. The harvested tissue must
be processed promptly, at the very latest 24 hours after harvesting.4.5.2 Cryopreservation of harvested tissue
Slow freezing is currently recommended for the cryopreservation
of ovarian tissue because of the higher efficacy of this method in
routine clinical practice [12–14].Dittrich R et al. Fertility Preservation for… Geburtsh Frauenheilk 2018; 78: 567–584
4.5.3 Transplantation of tissueConsensus-based Recommendation 4.R37
Expert consensus Strength of consensus +++
Ovarian tissuemust be transplanted orthotopically, i.e. on or into the ovary
or close to the ovary in the retroperitoneal space.
Consensus-based Recommendation 4.R38
Expert consensus Strength of consensus +++
The patientʼs fertility (tubal, uterine and extrauterine factors) must be as-
sessed when transplanting ovarian tissue and, if possible, corrections must
carried out where necessary.
Consensus-based Recommendation 4.R40
Expert consensus Strength of consensus ++
If the patient wishes to have children, the dose administered to the uterus
must be kept as low as possible using the latest radiation planning and
techniques.
Consensus-based Recommendation 4.R41
Expert consensus Strength of consensus +++
The patient must be offered combinations of different fertility-preserving
methods (e.g. cryopreservation of oocytes, cryopreservation of ovarian
tissue and/or the administration of GnRH agonists) to improve the efficacy
of fertility protection methods.4.5.4 Risk of tumor or disease recurrence after
retransplantation
(▶ Table 9)▶ Table 9 Risk of ovarian metastasis for various tumor types (modified
from Dolmans et al. [14] and Bastings et al. [15]).
High risk Moderate risk Low risk
▪ leukemia
▪ neuro-
blastoma
▪ Burkittʼs
lymphoma
▪ ovarian
tumors
▪ stage IV breast cancer
(lobular subtypes)
▪ bowel cancer
▪ endometrial carcinoma
▪ gastric cancer
▪ cervical adenocarcinoma
▪ non-Hodgkinʼs
lymphoma
▪ Ewingʼs sarcoma
▪ stage I–III breast can-
cer (ductal subtypes)
▪ cervical squamous
cell carcinoma
▪ Hodgkinʼs lymphoma
▪ osteosarcoma
▪ non-genital
rhabdomyosarcoma
▪ Wilmsʼ tumor
Consensus-based Statement 4.S24
Expert consensus Strength of consensus +++
The risk of ovarian metastasis cannot be excluded for any type of tumor.
To date, an increased risk has been found for leukemia, neuroblastoma,
Burkittʼs lymphoma andmalignant ovarian tumors.
Consensus-based Recommendation 4.R39
Expert consensus Strength of consensus +++
The patient must be informed before harvesting the tissue about the pos-
sible risk of transferring malignant cells by transplanting the harvested
ovarian tissue.
Dittrich R et al. Fertility Preservation for… Geburtsh Frauenheilk 2018; 78: 567–5844.6 Fertility-preserving or fertility-creating/fertility-
restoring methods following uterine radiotherapy4.7 Combinations of fertility-protecting methods6 Recommendations for Selected Tumor Entities
in Women
6.1 Breast cancer
6.1.1 Fertility protection counseling for women
with breast cancerConsensus-based Recommendation 6.R3
Expert consensus Strength of consensus ++
Every fertile woman with breast cancer whomight wish to have children
must receive counseling about ovarian toxicity and the available methods
to protect fertility before starting any potentially gonadotoxic therapy.
Consensus-based Recommendation 6.R4
Expert consensus Strength of consensus ++
Patients with metastatic breast cancer must receive individualized
information on fertility protection which must also take account of the
prognosis of a more limited life expectancy.6.1.2 Pregnancy after breast cancerConsensus-based Statement 6.S36
Expert consensus Strength of consensus ++
According to retrospective observational studies, pregnancy after treat-
ment for breast cancer is not associatedwith a poorer prognosiswith regard
to the underlying disease.
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Consensus-based Statement 6.S33
Expert consensus Strength of consensus +++
Irrespective of the patientʼs hormone status, there are no conclusive data
about the potential impact of hormone stimulation for oocyte retrieval
before starting planned neoadjuvant systemic therapy for breast cancer
on the patientʼs oncologic prognosis.
Consensus-based Recommendation 6.R56
Expert consensus Strength of consensus ++
GebFra Science | Guideline6.1.3 Limited fertility due to chemotherapy
for breast cancer
The standard chemotherapy protocols to treat breast cancer in
young women are anthracycline- and taxane-based chemothera-
pies. The rule of thumb for persistent amenorrhea following an-
thracycline-taxane-based regimens is estimated to be 10–20%
for women aged < 30 years, while the rate of persistent amenor-
rhea for women aged more than 30 years ranges from 13–68%,
depending on the patientʼs age [16,17].
6.1.4 Limited fertility due to radiotherapyConsensus-based Statement 6.S32
Expert consensus Strength of consensus +++
Regional radiotherapy to treat breast cancer is not associated with reduced
fertility.
Hormone stimulation for oocyte retrieval can be done in patients with hor-
mone receptor-positive breast cancer receiving concomitant anti-hormone
treatment (e.g. aromatase inhibitors or tamoxifen).6.1.5 Special aspects of fertility protection for women
with hormone receptor-positive breast cancer,
limited fertility due to endocrine therapyConsensus-based Recommendation 6.R55
Expert consensus Strength of consensus ++
If the patient has been carefully informed about the potential risks, pausing
anti-tumor endocrine therapy (after a minimum of 2 years of therapy) may
be considered to allow the patient to have children, after which the patient
would resume therapy.6.1.6 Potential fertility protection methods for patients
with breast cancer
(▶ Table 10)▶ Table 10 Retrospective studies on methods of cryopreservation in women
Authors Study Number of wom
Lawrenz et al., 2012 [18] retrospective, single center n = 56
Turan et al., 2013 [19] retrospective cohort study
single center
n = 78
Sigismondi et al., 2015 [20] retrospective, single center n = 31
Takae et al., 2015 [21] retrospective, single center n = 27
Dahhan et al., 2015 [22] retrospective, single center n = 16
Oktay et al., 2015 [23] retrospective, single center n = 131
5786.1.7 GnRH agonists (GnRHa) for women
with breast cancer
A recent systematic meta-analysis about the use of GnRHa in
women with breast cancer [26] evaluated the data from 1962
women, 541 of whom received chemotherapy without GnRHa
and 521 of whom were treated with chemotherapy and GnRHa
[26]. The rate of spontaneous menstruation recurrence after com-
pleting chemotherapy was higher in the group treated with con-
comitant GnRHa (OR: 2.57; 95% CI: 1.65–4.01; p < 0.0001). How-
ever, there was no significant difference in pregnancy rates be-
tween the two groups. Another recent meta-analysis (n = 1231,
[27]) found a significantly reduced risk of premature ovarian insuf-
ficiency (OR: 0.36; 95% CI: 0.41–0.73, p < 0.001) for patients who
received concomitant GnRHa during chemotherapy, together
with a slightly but significantly increased pregnancy rate (OR:
1.83; 95% CI: 1.02–3.28; p = 0.041).with breast cancer.
en Methods Country
ovarian tissue cryopreservation, GnRHa, hormone
stimulation and cryopreservation of oocytes,
combinations also possible
Germany
hormone stimulation and cryopreservation
of oocytes
USA
ovarian tissue cryopreservation, hormone
stimulation and cryopreservation of oocytes
Italy
combination of ovarian tissue cryopreservation
and hormone stimulation with cryopreservation
of oocytes
Japan
hormone stimulation and cryopreservation
of oocytes
Netherlands
hormone stimulation with/without letrozole
and cryopreservation of oocytes
USA
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Consensus-based Statement 6.S36
Expert consensus Strength of consensus ++
Depending on the patientʼs age, chemotherapy to treat osteosarcoma and
soft tissue sarcoma will result in primary ovarian insufficiency.
Consensus-based Recommendation 6.R616.1.8 Reduced ovarian reserve in women
with BRCA1 mutation
Comparative studies have pointed out that women with BRCA1
mutation may have reduced ovarian reserve compared to healthy
women [24,25].
6.2 Ovarian/borderline tumors
6.2.1 Borderline tumorsConsensus-based Recommendation 6.R57
Expert consensus Strength of consensus +++
After women who have had fertility-preserving surgery to treat an ovarian/
borderline tumor and who wish to have children have been informed about
the potential risks involved, physicians may consider offering hormone
stimulation to them as part of fertility treatment.
Consensus-based Recommendation 6.R58
Expert consensus Strength of consensus +++
Before undergoing bilateral salpingo-oophorectomy, women should be
offered the possibility of cryopreserving unfertilized and fertilized oocytes.
Consensus-based Recommendation 6.R59
Expert consensus Strength of consensus +++
Cryopreservation of ovarian tissue may be considered.
Expert consensus Strength of consensus +++
Patients with sarcoma should be offered cryopreservation of ovarian tissue
to protect fertility. The risk of recurrence caused by transplantation of the
tissue cannot be excluded andmust be discussed with the patient before
harvesting ovarian tissue.
Consensus-based Recommendation 6.R62
Expert consensus Strength of consensus +++
After the onset of puberty, patients with sarcoma should be informed
about the possibility of cryopreserving oocytes, if the start of oncologic
therapy can be postponed by at least 2 weeks.
Consensus-based Recommendation 6.R63
Expert consensus Strength of consensus ++
AGnRH agonist can be administered to patients with sarcoma during
gonadotoxic therapy.6.2.2 Ovarian cancerConsensus-based Statement 6.S34
Expert consensus Strength of consensus ++
Fertility treatment is possible in patients with early ovarian cancer (FIGO Ia,
G1/G2) who were treated using a fertility-preserving approach and were
given detailed information about the risks.
Consensus-based Recommendation 6.R64
Expert consensus Strength of consensus +++
Every fertile woman with colorectal cancer whomay wish to have a child
must be informed about the ovarian toxicity of treatment and methods of
preserving fertility before starting a potentially gonadotoxic therapy.
Consensus-based Statement 6.S37
Expert consensus Strength of consensus ++6.3 Solid tumors
6.3.1 SarcomasConsensus-based Recommendation 6.R60
Expert consensus Strength of consensus +++
Every fertile woman with sarcoma whomay wish to have a child must
be informed about the ovarian toxicity of treatment and the methods of
preserving fertility before starting a potentially gonadotoxic therapy.
Consensus-based Statement 6.S35
Expert consensus Strength of consensus ++
There are no indications that pregnancy after treatment for sarcoma will
result in a poorer prognosis.
Dittrich R et al. Fertility Preservation for… Geburtsh Frauenheilk 2018; 78: 567–5846.3.2 Colorectal cancerAccording to case reports, pregnancy after rectal cancer is not associated
with a poorer oncologic prognosis.
Consensus-based Statement 6.S38
Expert consensus Strength of consensus ++
Chemotherapeutic treatment of colorectal cancer with 5-fluorouracil,
folinic acid and oxaliplatin is reported to have a low risk of ovarian insuffi-
ciency.
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Consensus-based Recommendation 6.R65
Expert consensus Strength of consensus +++
Patients with colorectal cancer should be offered cryopreservation of
ovarian tissue to protect fertility. The risk of disease recurrence caused by
transplantation cannot be excluded andmust be discussed with the patient
before harvesting ovarian tissue.
Consensus-based Recommendation 6.R66
Expert consensus Strength of consensus +++
After the onset of puberty, patients with colorectal cancer should be
informed about the possibility of cryopreserving oocytes if the start of
oncologic therapy can be postponed by at least 2 weeks.
Consensus-based Recommendation 6.R67
Expert consensus Strength of consensus ++
AGnRH agonist can be administered to patients with colorectal cancer
during gonadotoxic therapy.
Consensus-based Statement 6.S40
Expert consensus Strength of consensus +++
The risk of infertility after treatment for ALL depends on the protocol used
for treatment. Women who were treated with a conditioning protocol to
prepare them for stem cell transplantation have a high risk of infertility.
Patients treated with a conventional protocol have a low risk of infertility.
Consensus-based Statement 6.S41
Expert consensus Strength of consensus +++
Depending on the dose, cranial irradiation during treatment for ALL can
lead to treatable impairment of the hypothalamic-hypophyseal axis.
Consensus-based Recommendation 6.R71
Expert consensus Strength of consensus ++
Patients with ALL who have a high risk of POI from therapy and who cannot
postpone their gonadotoxic therapy can be offered the option of cryo-
preserving ovarian tissue to protect their fertility.
GebFra Science | Guideline6.4 Hematologic disease
6.4.1 Lymphomas (Hodgkinʼs and non-Hodgkinʼs
lymphoma)Consensus-based Statement 6.S39
Expert consensus Strength of consensus +++
With lymphomas, the risk of primary ovarian insufficiency depends on
the chemotherapy protocol used.
Consensus-based Recommendation 6.R68
Expert consensus Strength of consensus +++
Cryopreservation of ovarian tissue to protect fertility must be offered to
patients with lymphomawho are expected to have a high risk of premature
ovarian insufficiency from oncologic therapy. The risk of ovarianmetastasis
is low for Hodgkinʼs lymphoma and high for non-Hodgkinʼs lymphoma and
Burkittʼs lymphoma.
Consensus-based Recommendation 6.R69
Expert consensus Strength of consensus +++
After the onset of puberty, patients with lymphoma should be informed
about the possibility of cryopreserving oocytes if the start of oncologic
therapy can be postponed by at least 2 weeks.
Consensus-based Recommendation 6.R70
Expert consensus Strength of consensus +++
AGnRH agonist can be administered to patients with lymphoma during
gonadotoxic therapy. This can help prevent thrombocytopenic menor-
rhagia.
5806.4.2 Leukemia
6.4.2.1 Acute lymphatic leukemia (ALL)Consensus-based Recommendation 6.R72
Expert consensus Strength of consensus +++
The risk of tumor recurrence after autotransplantation of ovarian tissue
is considered to be high in patients with ALL, and autotransplantation is
therefore not recommended.
Consensus-based Recommendation 6.R73
Expert consensus Strength of consensus ++
After the onset of puberty, patients with ALL should be informed about the
possibility of cryopreserving oocytes if the start of oncologic therapy can
be postponed by at least 2 weeks.
Consensus-based Recommendation 6.R74
Expert consensus Strength of consensus +++
AGnRH agonist can be administered to patients with ALL during gonado-
toxic therapy. This can help prevent thrombocytopenic menorrhagia.6.4.2.2 Acute myeloid leukemia (AML)Consensus-based Statement 6.S42
Expert consensus Strength of consensus +++
The risk of infertility after treatment for AML depends on the protocol used
for treatment. Women treated with a conditioning protocol to prepare
them for stem cell transplantation have a high risk of infertility. Patients
treated with a conventional protocol have a low risk of infertility.
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Consensus-based Recommendation 6.R75
Expert consensus Strength of consensus +++
Patients with AML who have a high risk of POI from therapy andwho cannot
postpone their gonadotoxic therapy can be offered the option of cryo-
preserving ovarian tissue to protect their fertility.
Consensus-based Recommendation 6.R76
Expert consensus Strength of consensus +++
The risk of tumor recurrence after autotransplantation of ovarian tissue
is considered to be high in patients with AML, and autotransplantation
is therefore not recommended.
Consensus-based Recommendation 6.R77
Expert consensus Strength of consensus +++
After the onset of puberty, patientswith AML should be informedabout the
possibility of cryopreserving oocytes if the start of oncologic therapy can
be postponed by at least 2 weeks.
Consensus-based Recommendation 6.R78
Expert consensus Strength of consensus +++
AGnRH agonist can be administered to patients with AML during gonado-
toxic therapy. This can help prevent thrombocytopenic menorrhagia.
Consensus-based Recommendation 6.R81
Expert consensus Strength of consensus ++
After the onset of puberty and before starting conditioning for stem cell
transplantation, patients should be informed about the possibility of
cryopreserving oocytes if the start of oncologic therapy can be postponed
by at least 2 weeks.
Consensus-based Recommendation 6.R82
Expert consensus Strength of consensus +++
Patients can be offered the option of cryopreserving ovarian tissue
to protect fertility before undergoing stem cell transplantation.
Consensus-based Recommendation 8.R92
Expert consensus Strength of consensus +++
The efficacy of administering drugs for fertility protection (e.g. a GnRH
agonist) in childhood or early adolescence is still questionable.
GnRH agonists must not be administered to prepubertal patients.6.4.2.3 Chronic myelogenous leukemia (CML)Consensus-based Statement 6.S43
Expert consensus Strength of consensus +++
The risk of ovarian insufficiency following the administration of tyrosine
kinase inhibitors (TKI) is unclear, with TKI reported to have a teratogenic
potential.
Consensus-based Recommendation 6.R79
Expert consensus Strength of consensus +++
The risk of disease recurrence after autotransplantation of ovarian tissue
is considered to be high in patients with CML, and autotransplantation
is therefore not recommended.
Consensus-based Recommendation 8.R93
Expert consensus Strength of consensus +++
Depending on the expected radiation dose administered to the ovary, the
possibility of ovariopexy must be discussed during the tumor conference.
The recommendation for ovariopexy must be discussed with the patient
and her family.
Consensus-based Recommendation 8.R94
Expert consensus Strength of consensus +++
After puberty patients can undergo stimulation treatment to cryopreserve
oocytes. Thismust be donebefore starting treatment formalignant disease
if cancer therapy can be postponed by 2 weeks.6.4.2.4 Stem cell transplantationConsensus-based Recommendation 6.R80
Expert consensus Strength of consensus +++
Women treated with a conditioning protocol to prepare them for stem
cell transplantation have a high risk of infertility. These patients must be
informed and receive counseling about methods to protect their fertility.
Dittrich R et al. Fertility Preservation for… Geburtsh Frauenheilk 2018; 78: 567–5848 Malignant Disease in Children and Adolescents
In addition to the established methods to protect fertility before
and after treatment for malignant disease mainly targeting post-
pubertal boys and girls, experimental methods are also available,
particularly for prepubertal children. Listed below are instructions
concerning the use of fertility protection methods which need to
be taken into account before starting therapy.Consensus-based Recommendation 8.R95
Expert consensus Strength of consensus +++
It is currently not clear what the indications for cryopreserving ovarian tis-
sue from prepubertal and peripubertal girls are. The decision for or against
cryopreservation requires the type of therapy and the gonadotoxic dose to
be weighed up in each individual case.
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Consensus-based Recommendation 8.R96
Expert consensus Strength of consensus +++
After puberty, potential options for fertility preservation include cryo-
preserving sperm (ejaculation, electrostimulation, testicular biopsy with
testicular sperm extraction [TESE]) and cryopreserving testicular tissue as
a fertility reserve for assisted reproduction techniques to be used at a later
date. The patient and his family must be informed about these options.
Consensus-based Statement 8.S48
Expert consensus Strength of consensus +++
The cryopreservation of immature testicular tissue extracted by biopsy
before the onset of puberty is still in its experimental stages. The subse-
quent maturation of sperm from spermatogonial stem cells, which would
be necessary for this approach, is currently not yet possible in humans.
Transplanting cryopreserved tissue always carries the risk of transplanting
malignant cells.
GebFra Science | Guideline9 Psychological and Ethical Aspects
of Fertility PreservationConsensus-based Statement 9.S49
Expert consensus Strength of consensus +++
All patients of reproductive age with malignant disease and children with
malignant disease and their parents should be offered counseling and ad-
vice on fertility protection using a biopsychosocial framework. Information
about the options for and the limits of fertility protection should be made
available to affected patients both orally and in writing (e.g., in the form of
publications like “Die Blauen Ratgeber” – a German series of publications
issued by the German Cancer Society) through low-threshold publications
which enable patients to make their decisions based on informed consent.
Consensus-based Statement 9.S50
Expert consensus Strength of consensus +++
During open-ended counseling, the different options and perspectives
available must be presented and discussed without bias or preference: on-
cologic therapywithout fertility protection, oncologic therapy after fertility
protection measures, and pregnancy, childbirth and starting a family must
be discussed in ways that take account of different healing processes and
courses of disease.Appendix to the Guideline
A standard operating procedure (SOP) on managing the contact
with a patient before the patient starts oncologic treatment
which will reduce their fertility while the patient may still want to
have children is included in the appendix of the long (German)
version of the guideline, together with leaflets on preserving
fertility which were compiled together with the German Cancer
Society (DKG).582References
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